Review on anticoccidial vaccine development for chickens: Past progress, modern methods, and production bottlenecks.
- 1Department of Veterinary Laboratory Technology, Injibara University, Injibara, Ethiopia. Electronic address: [email protected].
- 2Department of Parasitology, Microbiology and Poultry Health, College of Veterinary Medicine and Agriculture, Addis Ababa University, Ethiopia.
Abstract
Poultry coccidiosis is an economically significant intestinal disease caused by parasitic protozoa in the genus Eimeria. Developing Eimeria vaccines is a possible way to control and prevent coccidiosis. This review discusses the different methods and challenges of anticoccidia vaccine production for poultry. The production of anticoccidial vaccines involves several methods with challenges. Live Eimeria vaccines are produced using non-attenuation without any alteration or modifications in terms of pathogenicity, and attenuation methods reduce virulence through serial passage in embryonated eggs or chickens, irradiation, chemicals, heat, and live strains tolerant of ionophores. Both non-attenuation and attenuation methods are challenge, including the need for chickens' infection to produce oocysts, high cost, and quality control tests for ensuring vaccine safety. To minimize the challenge of live vaccine production, use recombinant deoxyribonucleic acid (DNA) technology. Unlike conventional whole-cell vaccines, non-replicating subunits only contain the pathogen antigenic parts for the subunit vaccine and genetic materials for DNA vaccine production and are cloned in the presence of a harmless plasmid vector or with a harmless adjuvant. The genetic and antigenic diversity among and within species of Eimeria, chicken flocks and locations, and complex life cycle of the Eimeria species make the development of DNA and recombinant vaccines extremely difficult. Challenge infection effects in immunized chickens are determined by weight gain, feed conversion efficiency, oocyst production, and intestine lesions, but there is a lack of immunological assays for accurately predicting studies for laboratory and field trials and standard guidelines for modern poultry vaccine production in Eimeria. The production of a safe and effective vaccine against coccidiosis in poultry is crucial for minimizing economic losses and enhancing animal welfare. To select the appropriate anticoccidial vaccine development methods and assess the challenges faced, more research should be done.
Related
- Serum biochemical and hematological responses of broiler chickens to herbal-origin anticoccidial supplementation during experimental Eimeria infection.
- A novel photoperiod-sensitive laying curve for modelling egg production in native chickens and the effect of black soldier fly larvae supplementation under agroecological conditions
- Study on the Effects of Dandelion Ultrafine Powder on the Production Performance and Intestinal Microbiota of Broiler Chickens.
- Genome-wide association study identifies candidate loci and a functional regulatory variant associated with egg-production traits in Wenchang chickens
- A joint genome-wide association study reveals candidate genes associated with egg production traits in chickens
BibTeX
@article{yismaw2026review,
title = {{Review on anticoccidial vaccine development for chickens: Past progress, modern methods, and production bottlenecks.}},
author = {Melaku Yismaw and Getachew Terefe},
journal = {Poultry science},
year = {2026},
month = oct,
doi = {10.1016/j.psj.2026.107875},
url = {https://europepmc.org/article/MED/42854494},
note = {CC BY},
}
RIS
TY - JOUR
TI - Review on anticoccidial vaccine development for chickens: Past progress, modern methods, and production bottlenecks.
AU - Melaku Yismaw
AU - Getachew Terefe
PY - 2026
DA - 2026/10/05
JO - Poultry science
DO - 10.1016/j.psj.2026.107875
UR - https://europepmc.org/article/MED/42854494
AB - Poultry coccidiosis is an economically significant intestinal disease caused by parasitic protozoa in the genus Eimeria. Developing Eimeria vaccines is a possible way to control and prevent coccidiosis. This review discusses the different methods and challenges of anticoccidia vaccine production for poultry. The production of anticoccidial vaccines involves several methods with challenges. Live Eimeria vaccines are produced using non-attenuation without any alteration or modifications in terms of pathogenicity, and attenuation methods reduce virulence through serial passage in embryonated eggs or chickens, irradiation, chemicals, heat, and live strains tolerant of ionophores. Both non-attenuation and attenuation methods are challenge, including the need for chickens' infection to produce oocysts, high cost, and quality control tests for ensuring vaccine safety. To minimize the challenge of live vaccine production, use recombinant deoxyribonucleic acid (DNA) technology. Unlike conventional whole-cell vaccines, non-replicating subunits only contain the pathogen antigenic parts for the subunit vaccine and genetic materials for DNA vaccine production and are cloned in the presence of a harmless plasmid vector or with a harmless adjuvant. The genetic and antigenic diversity among and within species of Eimeria, chicken flocks and locations, and complex life cycle of the Eimeria species make the development of DNA and recombinant vaccines extremely difficult. Challenge infection effects in immunized chickens are determined by weight gain, feed conversion efficiency, oocyst production, and intestine lesions, but there is a lack of immunological assays for accurately predicting studies for laboratory and field trials and standard guidelines for modern poultry vaccine production in Eimeria. The production of a safe and effective vaccine against coccidiosis in poultry is crucial for minimizing economic losses and enhancing animal welfare. To select the appropriate anticoccidial vaccine development methods and assess the challenges faced, more research should be done.
SN - 0032-5791
SN - 1525-3171
ER -